Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Anti-CD14 Treatment With a Recombinant Chimeric Monoclonal Antibody (IC14) in Hospitalized Patients With Acute Respiratory Distress Syndrome

NCT06513949 is registered in ClinicalTrials.gov with Implicit Bioscience as lead sponsor.

NCT NCT06513949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06513949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Anti-CD14 Treatment With a Recombinant Chimeric Monoclonal Antibody (IC14) in Hospitalized Patients With Acute Respiratory Distress Syndrome
Lead sponsor
Implicit Bioscience
Phase
Phase 2
Overall status
Recruiting
Start date
June 17, 2026
Completion date
June 1, 2029
Enrollment
56 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute lung injury, acute lung injury/acute respiratory distress syndrome (ards), acute respiratory distress syndrome, adult respiratory distress syndrome